Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

80.80 +0.80 (+1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 140,845
Open 79.72
Bid (Size) 80.48 (100)
Ask (Size) 81.18 (100)
Prev. Close 80.00
Today's Range 79.72 - 82.87
52wk Range 33.96 - 123.75
Shares Outstanding 11,834,361
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases. 
Via The Motley Fool
Topics Regulatory Compliance Stocks

Performance

YTD
-3.2%
-3.2%
1 Month
+21.2%
+21.2%
3 Month
-9.1%
-9.1%
6 Month
+6.3%
+6.3%
1 Year
+128.2%
+128.2%

More News

Read More
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
Via MarketMinute
News headline image
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
From Bright Minds Biosciences
Via GlobeNewswire
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
Why Did DRUG Stock Rocket 51% Today? ↗
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Why Bright Minds Biosciences Stock Topped the Market on Monday ↗
Via The Motley Fool
News headline image
Large Patient Population Is Key Driver For Bright Minds' Growth ↗
Via Benzinga
News headline image
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗
Via Benzinga
News headline image
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Biotechs on the Brink: 2 Stocks With Huge Potential
Via MarketBeat
News headline image
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗
Via The Motley Fool
News headline image
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
Via Benzinga
Topics Government
News headline image
What's Going On With Bright Minds Biosciences Stock? ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 10/14 - 10/18
Via MarketBeat
Topics Artificial Intelligence Economy

Frequently Asked Questions

Is Bright Minds Biosciences Inc. - common stock publicly traded?
Yes, Bright Minds Biosciences Inc. - common stock is publicly traded.
What exchange does Bright Minds Biosciences Inc. - common stock trade on?
Bright Minds Biosciences Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bright Minds Biosciences Inc. - common stock?
The ticker symbol for Bright Minds Biosciences Inc. - common stock is DRUG on the Nasdaq Stock Market
What is the current price of Bright Minds Biosciences Inc. - common stock?
The current price of Bright Minds Biosciences Inc. - common stock is 80.80
When was Bright Minds Biosciences Inc. - common stock last traded?
The last trade of Bright Minds Biosciences Inc. - common stock was at 08/06/26 04:00 PM ET
What is the market capitalization of Bright Minds Biosciences Inc. - common stock?
The market capitalization of Bright Minds Biosciences Inc. - common stock is 956.22M
How many shares of Bright Minds Biosciences Inc. - common stock are outstanding?
Bright Minds Biosciences Inc. - common stock has 956M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.